Intuitive Surgical, Inc. — FY 2014 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2014; quarterly figures include the three months ended December 31, 2014. Intuitive designs, manufactures, and sells da Vinci surgical systems, instruments and accessories, and related service and training. Its revenue combines system sales with recurring instruments, accessories, and service revenue.
Key financial metrics
| Metric | FY 2014 | FY 2013 | Change |
|---|---|---|---|
| Revenue | $2.132 billion | $2.265 billion | Down 6% |
| Gross profit / margin | $1.414 billion / 66% | $1.594 billion / 70% | Margin down 4 percentage points |
| Operating income / margin | $544.8 million / 26% | $852.5 million / 38% | Down 36% |
| Net income / diluted EPS | $418.8 million / $11.11 | $671.0 million / $16.73 | Down 38% / 34% |
| Cash from operating activities | $665.1 million | $880.0 million | Down $214.9 million |
| Cash, cash equivalents and investments | $2.497 billion | $2.754 billion | Down $256.9 million |
At December 31, 2014, current assets were $1.847 billion and current liabilities were $501.2 million. The balance sheet lists no interest-bearing debt. Total liabilities were $580.0 million and stockholders’ equity was $3.379 billion.
FY 2014 product revenue was $1.703 billion and service revenue was $429.0 million. Systems revenue fell 24% to $632.5 million; instruments and accessories revenue rose 4% to $1.070 billion; service revenue rose 8% to $429.0 million. Recurring revenue increased 5% to $1.499 billion, or 70% of total revenue. The company shipped 431 systems, compared with 546 in 2013, while procedure volume rose about 9% to approximately 570,000.
For Q4 2014, revenue was $604.7 million, gross profit $393.4 million, net income $146.8 million, and diluted EPS $3.94. Compared with Q4 2013, revenue rose from $576.2 million, while net income declined from $166.2 million and diluted EPS from $4.28.
Material changes versus prior periods
- Lower system sales, especially in the U.S. and Japan, drove the annual revenue decline; recurring revenue growth partly offset that weakness.
- Procedure growth slowed to about 9% from 16% in 2013. U.S. general surgery and worldwide urology grew, while U.S. gynecology declined about 2%, reflecting pressure on benign procedures and a high level of minimally invasive hysterectomy adoption.
- Gross margin weakened, in part because newer products—including the da Vinci Xi and advanced instruments—had lower initial margins, and because of trade-in credits, incentive compensation, recall costs, and the medical-device excise tax.
- SG&A increased 20% to $691.0 million, including an $82.4 million pretax charge for estimated settlements of certain product-liability claims. Operating income also reflected higher costs and lower revenue.
- The company spent $1.0 billion repurchasing 2.5 million shares. Cash and investments declined from $2.754 billion to $2.497 billion, primarily due to repurchases, partly offset by operating cash flow.
Outlook, risks, contingencies, and unusual items
Management provided no specific quantified revenue or earnings guidance in the supplied filing text. It expects continued substantial investment in R&D and procedure adoption, and believes cash, investments, and expected operating cash flows will meet liquidity needs beyond one year. Future system demand is described as dependent on procedure growth, hospital capital spending, adoption of the Xi system, utilization, and regulatory clearances and reimbursement.
- Product-liability matters: The $82.4 million 2014 charge relates to estimated settlements of claims, many associated with certain Monopolar Curved Scissor instruments. The company stated that additional losses are reasonably possible but it could not estimate an excess loss range. $49.5 million remained accrued at year-end. Approximately 102 individual product-liability lawsuits and a multi-plaintiff case involving 20 patients were disclosed.
- Stapler recall: In September 2014 the company suspended use and stopped shipments of the EndoWrist Stapler 45 for the Si system after identifying clamp-mechanism failures. A voluntary field recall followed in December; replacement instruments began shipping in early 2015.
- Regulatory: The FDA closed its 2013 Warning Letter observations in April 2014, but its 2014 inspection identified five quality-system observations for which the company submitted a corrective-action plan. Xi approvals varied by market, with Japan’s submission pending at year-end.
- Other exposure: Two insurers sought rescission of product-liability policies; securities and derivative litigation remained pending. The filing says outcomes and potential losses for certain matters could not be reliably estimated.
- Other unusual items: The company recorded $8.5 million of impairment charges on two equity investments. Q4 included one-time tax benefits of $19.9 million from audit settlements and statute expirations and $5.0 million from reinstatement of the federal R&D tax credit.
- Business risks: Key risks include market acceptance and clinical evidence, competition, reimbursement and healthcare policy, product safety and publicity, regulatory compliance, supplier concentration, foreign exchange, and the timing and seasonality of hospital system purchases.
Important facts for investors to verify
- Whether system sales stabilize and whether recurring revenue and procedure growth can offset fewer capital purchases.
- The ultimate settlement costs and insurance coverage for product-liability claims, including any losses beyond the $82.4 million accrual.
- The status and effectiveness of Stapler 45 corrective actions and replacement products.
- Xi and other product clearances, Japanese procedure reimbursement, and the effect of hospital spending and payer trends on adoption.
- The sustainability of margins as new products scale, and the cash-flow and capital-allocation effects of the renewed $1.0 billion share-repurchase authorization announced in January 2015.